OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to…
- 01.OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind
- 02.The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems
- 03.Developing a new drug in the US takes ten to…
This material is provided as an extended analytical summary.
Read full article at sourceRelated Intelligence
All stories →Создание агентной системы извлечения на базе Amazon Bedrock с CDK
AWS Machine Learning описывает создание агентной системы извлечения на базе Amazon Bedrock с использованием AWS CDK.
Кэширование запросов для ИИ-агентов на Amazon Bedrock
Кэширование запросов позволяет ИИ-агентам на Amazon Bedrock быть более эффективными.
GPT-6.1 Terra: OpenAI halved the price of a mid-range agent model
🖥️ GPT-6.1 Terra: OpenAI halved the price of a mid-range agent model OpenAI released GPT-6.1 Terra for agent-based scenarios, computer work and everyday coding. The API price is half that of GPT-5.6 Terra: $1 per million input tokens instead of $2 and $6 per...